Welcome to our dedicated page for Quince SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quince Therapeutics, Inc. (Nasdaq: QNCX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Quince’s financial condition, clinical development activities, and material corporate events related to its rare disease biotechnology programs.
For Quince, key filings include periodic reports such as Forms 10-Q and 10-K, which discuss research and development spending, cash resources, and risk factors associated with advancing eDSP and the Autologous Intracellular Drug Encapsulation (AIDE) platform. Current reports on Form 8-K highlight specific events, including quarterly financial results, amendments to the European Investment Bank credit facility, and updates tied to investor communications like the company’s virtual Investor Day.
Filings related to the pivotal Phase 3 NEAT trial in Ataxia-Telangiectasia (A-T) and other clinical programs can be important for understanding trial design, regulatory interactions, and the status of eDSP as a potential treatment. Disclosures may reference the Special Protocol Assessment (SPA) agreement with the FDA, Fast Track designation for the eDSP System in A-T, and the company’s intentions regarding future regulatory submissions, subject to study outcomes.
Stock Titan enhances these documents with AI-powered summaries that explain the main points of lengthy reports such as 10-K annual reports and 10-Q quarterly updates in straightforward language. Real-time updates from the SEC’s EDGAR system help ensure that new Quince Therapeutics filings, including Form 4 insider transaction reports and proxy materials, appear promptly. Users can review full-text filings while relying on AI-generated overviews to quickly identify items related to clinical milestones, financing arrangements, or changes in capital structure.
By combining original SEC documents with AI analysis, this page helps investors and researchers interpret Quince Therapeutics’ regulatory history and ongoing obligations as a Nasdaq-listed biotechnology company.
Quince Therapeutics, Inc. reported that its Board of Directors increased its size to four members and appointed June Bray as a Class I independent director effective April 22, 2026. She will serve until the 2026 Annual Meeting of Stockholders, or earlier if she departs the role.
Bray has been designated an independent director under Nasdaq rules and will serve on the Nominating & Governance, Audit, and Compensation Committees. Under the company’s Outside Director Compensation Policy, she will receive a $38,000 annual cash retainer for Board service, plus annual retainers of $7,500 for Nominating & Governance, $5,500 for Audit, and $4,000 for Compensation Committee work, without an option grant at appointment. She will also enter into the company’s standard indemnification agreement for directors.
Quince Therapeutics, Inc. is soliciting shareholder approval to amend its certificate of incorporation to permit a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-100, with the exact ratio set at the Board’s discretion.
The 2026 virtual Annual Meeting is scheduled for June 11, 2026; the Record Date for voting is April 23, 2026. The Board says the split is intended to help regain or maintain compliance with Nasdaq’s $1.00 minimum bid price rule and addresses a prior 1-for-10 split effected April 10, 2026. Authorized shares remain 250,000,000.
Quince Therapeutics, Inc. reports that its lead asset eDSP failed to meet primary and key secondary endpoints in the pivotal NEAT Phase 3 trial for A‑T, leading the company to discontinue all development of eDSP and other product candidates. With no active pipeline and limited resources, Quince is now primarily focused on preserving cash and exploring strategic alternatives, especially a potential reverse merger, for which it has hired LifeSci Capital as exclusive financial advisor.
The company flags substantial doubt about its ability to continue as a going concern and plans to seek additional equity or debt financing, including potential sales of common stock under an at‑the‑market agreement. Quince also discloses Nasdaq notices for noncompliance with minimum bid price and market value requirements and warns that delisting could occur. As of December 31, 2025, Quince had $17.8 million in cash, cash equivalents and short‑term investments, an accumulated deficit of $460.5 million, and a net loss of $84.0 million for 2025, while continuing to evaluate restructuring options and potential asset sales.
Quince Therapeutics, Inc. is implementing a reverse stock split of its common stock at a 1-for-10 ratio. Every ten shares will be automatically combined into one share, with no change to the $0.001 par value or basic rights of the common stock.
The reverse split becomes effective at 11:59 pm Eastern Time on April 10, 2026, and the shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on April 13, 2026 under the same symbol QNCX but a new CUSIP 22053A206. Immediately after the split, approximately 16,300,795 shares of common stock will be issued and outstanding. Fractional shares will not be issued; affected stockholders will receive cash in lieu of fractional shares.
Quince Therapeutics, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because additional time is needed to complete accounting procedures and disclosures following recent headcount reductions and the negative Phase 3 clinical trial results. The company expects to file within the 15 calendar day extension permitted by Rule 12b-25.
Quince Therapeutics, Inc. has eliminated its loan obligations to the European Investment Bank by paying EUR 4,800,000, or approximately $5.5 million, on March 27, 2026. This payment settled outstanding EIB debt of approximately $16.4 million as of that date, and all obligations under the finance and guarantee agreements were fully satisfied and discharged.
The company describes this settlement as a material milestone that removes a significant debt overhang while it continues a corporate restructuring and an evaluation of strategic alternatives, including potential merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics, Inc. has received two deficiency notices from Nasdaq regarding its continued listing on the Nasdaq Global Select Market. Nasdaq notified the company that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, giving Quince until September 14, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days.
The company also received a notice that its market value of listed securities has been below the required $50,000,000 for 30 consecutive business days, with the same compliance deadline and ten-day cure standard. Quince may seek to transfer to the Nasdaq Capital Market or consider actions such as a reverse stock split, and it can appeal any delisting determination. For now, its stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX.
Group One Trading LLC reports beneficial ownership of 5,942,906 shares of Quince Therapeutics common stock as of 02/28/2026. This holding is reported as 10.67% of the class and is shown with sole voting and dispositive power over those 5,942,906 shares. The filing states the reported total includes options to buy 6,344,500 shares and notes the filer acts as a market maker in Quince options.
Quince Therapeutics filed an 8-K outlining a failed lead drug program, a shift to strategic alternatives, and heightened financial risk. As of December 31, 2025, it preliminarily estimates $5.8 million in cash and cash equivalents, $11.9 million in short-term investments, and $16.4 million outstanding under its EIB Loan.
The company’s lead candidate eDSP failed to meet primary and secondary endpoints in the NEAT clinical trial, leaving no current product candidates or meaningful operations. Management has engaged LifeSci Capital to evaluate strategic options, focusing on a potential reverse merger, but notes there are no agreements in place and no assurance of success.
Quince warns that the only opportunity for shareholder return now depends on completing a reverse merger. It highlights risks including potential Nasdaq delisting due to its share price being below $1.00 since January 29, 2026, possible acceleration of the EIB Loan upon a Material Adverse Change, and a scenario where failure to execute a transaction could lead to bankruptcy proceedings in which common stockholders likely receive no value.
Quince Therapeutics, Inc. reported that five members of its Board of Directors — Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray — resigned effective January 30, 2026. The company states these resignations were not due to any disagreement over operations, policies, or practices.